Jason Butler
Stock Analyst at Citizens
(4.70)
# 176
Out of 5,109 analysts
147
Total ratings
52%
Success rate
50.28%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Market Outperform | $78 → $88 | $64.18 | +37.11% | 17 | Dec 22, 2025 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $7.50 | +153.33% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $145.31 | -9.85% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.69 | +96.08% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $68.41 | +34.48% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $5.97 | +101.01% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $30.93 | -9.47% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $27.87 | +32.76% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $12.75 | +206.00% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $4.19 | +43.20% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $38.12 | +162.33% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $32.28 | +17.72% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $8.64 | +108.33% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.96 | +1.01% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $849.95 | -17.52% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $15.38 | +114.56% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $2.74 | +228.47% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.21 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $12.19 | +55.87% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $3.26 | +574.85% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.97 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $13.90 | +302,058.27% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $16.60 | +598.80% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.79 | +87.89% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.78 | - | 1 | Dec 2, 2020 |
Cytokinetics
Dec 22, 2025
Maintains: Market Outperform
Price Target: $78 → $88
Current: $64.18
Upside: +37.11%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $7.50
Upside: +153.33%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $145.31
Upside: -9.85%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.69
Upside: +96.08%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $68.41
Upside: +34.48%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $5.97
Upside: +101.01%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $30.93
Upside: -9.47%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $27.87
Upside: +32.76%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $12.75
Upside: +206.00%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.19
Upside: +43.20%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $38.12
Upside: +162.33%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $32.28
Upside: +17.72%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.64
Upside: +108.33%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.96
Upside: +1.01%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $849.95
Upside: -17.52%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $15.38
Upside: +114.56%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $2.74
Upside: +228.47%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $7.21
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $12.19
Upside: +55.87%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $3.26
Upside: +574.85%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $3.97
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $13.90
Upside: +302,058.27%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $16.60
Upside: +598.80%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.79
Upside: +87.89%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.78
Upside: -